353 related articles for article (PubMed ID: 31356114)
1. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
Anthony C; Mladkova-Suchy N; Adamson DC
Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
[No Abstract] [Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
4. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
5. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic Therapy of High-Grade Gliomas.
Jo J; Wen PY
Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitors in tackling recurrent glioblastoma.
Hundsberger T; Reardon DA; Wen PY
Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of VEGF in the treatment of glioblastoma.
Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS
Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981
[TBL] [Abstract][Full Text] [Related]
10. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
11. Current status of antiangiogenic therapies for glioblastomas.
Arrillaga-Romany I; Reardon DA; Wen PY
Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
14. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
15. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK; Engelhard HH; Lakka SS
Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.
Nery de Albuquerque Rego G; da Hora Alves A; Penteado Nucci M; Bustamante Mamani J; Anselmo de Oliveira F; Gamarra LF
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599834
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy.
Guarnaccia L; Navone SE; Trombetta E; Cordiglieri C; Cherubini A; Crisà FM; Rampini P; Miozzo M; Fontana L; Caroli M; Locatelli M; Riboni L; Campanella R; Marfia G
Sci Rep; 2018 Jun; 8(1):8748. PubMed ID: 29884885
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Onishi M; Kurozumi K; Ichikawa T; Date I
Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
